Abdera is an oncology company developing targeted alpha therapies (TATs) for patients with relapsed, refractory, and metastatic cancers. Its targeted radiotherapies utilize purpose-built vectors to specifically target high-energy radio-isotopes to tumors and metastatic cancer lesions. This new class of drugs holds tremendous untapped therapeutic and commercial potential, and has generated over $10B in recent M&A, financings, and product launches – and are expected to comprise 70% of the $30B nuclear medicine market by 2030.

Ability biologics develops novel, tailored immune modifying biotherapeutics to address unmet medical requirements in cancer and autoimmune disease patients.

Amplitude Venture Capital deploys a growth model that has successfully been used to build Canadian companies with world-class management teams and scale companies to breakout potential. Since 2012 Amplitude's founding team has raised over $700 million of equity capital in private and public markets. Amplitude, with offices in Montreal, Toronto, and Vancouver, launched its first private capital fund in November 2019, a $200-million fund that applies a proven, evidence-based approach to investing in leading Canadian precision medicine companies.

Congruence Therapeutics operates as a biotechnology company working at the interface of computational and experimental drug discovery to design novel small molecules for diseases of protein misfolding.

Deep Genomics recruits from among the top 1% of recent graduates and seasoned experts at the intersection of genomics, drug development and AI.

DrugBank augments human intelligence to improve the world’s health. Our suite of products are powered by the world’s most complete and up-to-date pharmaceutical knowledge database. It includes everything there is to know about drugs and how they work in the body. We enable companies to improve healthcare delivery through precision medicine or clinical software applications, as well as uncover insights through data science in drug discovery. Our knowledge base can be integrated into software solutions to help achieve clinical intelligence. Companies can easily scale their usage through our API and launch faster with flexible data modules. By providing users with advanced insights and the right information at the right time, users are empowered to make better health decisions. Our extensive, structured datasets are used to discover novel drug candidates, identify drug repurposing opportunities, and build predictive machine learning models. Companies working with data science can find answers quickly and get drugs to market faster with our evidence-based drug information. Lastly, our publicly available resource, DrugBank Online, is free-to-use with limited datasets available for download for academic and non-commercial researchers. DrugBank has been cited in over 13,000 academic publications and is used by millions of researchers and health professionals globally.

Evommune is taking a tissue-based approach to insights and accelerating the development of transformative medicines for inflammatory diseases. Evommune creates novel strategies to treat inflammatory disorders by developing treatments that address symptoms while also halting disease progression. Evommune's pipeline contains initiatives aimed at combating highly prevalent inflammatory illnesses. Its mission is to drive real advancements for patients suffering from these diseases, with all of its programs designed to produce best-in-class profiles.

Gandeeva Therapeutics is a precision biotechnology company integrating the power of cryogenic electron microscopy (cryo-EM) and machine learning to develop differentiated therapeutics by targeting and modulating key protein-protein interactions. Gandeeva’s structure-guided drug discovery platform encompasses target prediction and validation (SPOTLIGHT™), hit identification by screening virtual and fragment libraries (HYPERFOCUS™), and lead optimization (CRYO-CADD™). Gandeeva has a robust preclinical oncology pipeline targeting difficult-to-treat cancers with novel protein interaction modulators such as interfacial glues (iGlues™) and allosteric inhibitors. Gandeeva is headquartered in the Greater Vancouver area, Canada. Please visit www.gandeeva.com or follow us on LinkedIn and Twitter for more information.

Nomic is a bioengineering company working to make the human proteome as broadly and easily accessible as the human genome. They are building the nELISA, a next-generation ELISA platform for measuring proteins at scale and at high throughput. They offer scientists protein profiling solutions to empower them to decide the scope and scale of their experiments.

Notch develops immune cell therapy developing a next-generation pipeline that is compatible and focuses on initial cancer cells. The company's proprietary T-cell production platform enables precision control of Notch signaling, which is required for T-cell development, by combining sophisticated product design with commercial-compatible processes. The ability to control notch signaling eliminates several critical limiting factors in cell therapy development and provides the ability to design and manufacture a consistent and limitless supply of therapeutic T cells. Notch Therapeutics was established in 2018 and is headquartered in Toronto, Canada.

Prilenia is a clinical-stage biotech company that develops novel treatments for neurodegenerative and neurodevelopmental disorders. Its lead asset is Pridopidine, a n oral drug candidate with an established safety profile and potential in multiple movement disorders and neurodegenerative diseases affecting adults and children. The company was founded in 2018 and is based in Israel, the Netherlands, and Boston.

Repare Therapeutics is a developer of oncology drugs designed to target specific vulnerabilities of tumor cells. The company's drugs combine a proprietary high throughput gene-editing and target discovery method with high-resolution protein crystallography, computational biology and clinical informatics, enabling patients to improve cancer treatment both with single therapy and in combination with existing drugs and treatments.